• Philippe Taupin.
• Dublin City University, School of Biotechnology, Glasnevin, Dublin, Ireland. philippe.taupin@dcu.ie
• Expert Opin Ther Pat. 2010 Sep 1; 20 (9): 1265-9.

BackgroundThe application is in the field of haematopoietic stem cell (HSC) and umbilical cord blood (CB) transplantation.ObjectiveIt aims at determining an enzymatic procedure to improve the engraftment of CB stem cells to the bone marrow (BM) as well as the rate of success of CB transplantation.MethodsHuman CB stem cells were treated with alpha1-3 fucosyltransferase VI (FTVI) for 30 min ex vivo prior to transplantation. Human CB stem cells were administered intravenously in irradiated nonobese diabetic/severe combined immune deficiency (NOD/SCID) mice.ResultsTreatment of CB stem cells with FTVI improves their engraftment in the BM of NOD/SCID mice.ConclusionTreatment of CB stem cells with FTVI, ex vivo prior to transplantation, may reduce the delay of engraftment of CB stem cells to the BM and the risk of early infections associated with CB transplants, particularly in adults. It may improve the outcome and rate of success of CB transplantation. The application claims the use of fucosyltransferase for improving the engraftment of CB HSCs to the BM for the treatment of haematologic diseases. The procedure may be used to improve the engraftment of HSCs from other sources and other types of stem cells, on transplantation, particularly when administered intravenously.

14 keywords...

hide…